---
schema_version: "secwatch.filing_event.v1"
accession: "0001171843-21-005574"
form_type: "8-K"
ticker: "ALGS"
cik: "0001799448"
company_name: "Aligos Therapeutics, Inc."
filed_at: "2021-08-05T23:59:59+00:00"
generated_at: "2026-06-29T21:55:00.874297+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.55
calibrated_materiality_score: 0.55
confidence: "high"
source: SEC EDGAR
---

# Aligos Q2 2021 net loss $29.8M; $83.6M stock offering; pipeline advances

## Summary
- Net loss $29.8M ($0.79 diluted EPS) vs $20.8M ($7.40) year ago; R&D spend $24.6M.
- Cash & investments $190.7M at June 30, 2021, down from $243.5M at Dec 2020.
- Gross proceeds of $83.6M from July 2021 follow-on stock offering (4.4M shares at $19.00).
- STOPS and CAM programs dosing in CHB cohorts; data expected H1 2022.
- CTA filed for ASO ALG-020572; NASH drug ALG-055009 CTA on track for Q3 2021.

## SEC filing metadata
- accession: 0001171843-21-005574
- form_type: 8-K
- ticker: ALGS
- cik: 0001799448
- company_name: Aligos Therapeutics, Inc.
- filed_at: 2021-08-05T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.55
- calibrated_materiality_score: 0.55
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1799448/000117184321005574/0001171843-21-005574-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1799448/000117184321005574/f8k_080521.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001171843-21-005574
- JSON: https://secwatch.observer/filing/0001171843-21-005574.json
- Plain text: https://secwatch.observer/filing/0001171843-21-005574.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.